APAlison L. Park

Alison L. Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alison L. Park has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COVID-19 immunisation among individuals with opioid use disorder in Ontario: a population-based cohort study

    by Melina Hanna, Anna Maria Subic, Alison L Park, Fangyun Wu, Douglas M Campbell, Pamela Leece, Laurie Morrison, Janet Parsons, Kate Sellen, Carol Strike, et al.

    Background: The COVID-19 pandemic exacerbated health inequities, particularly among individuals with opioid use disorder (OUD). Disparities in vaccine uptake among people with OUD remain poorly understood. This study assessed COVID-19 immunisation rates among individuals with OUD compared with the general population in Ontario, Canada. Methods: This population-based retrospective cohort study used linked administrative health data to compare COVID-19 vaccination rates between individuals diagnosed with OUD and a 10% random sample of individuals without OUD. Ontario residents aged >15 years with continuous healthcare coverage as of the censor date, 16 March 2020, were included. Inverse Probability of Treatment Weighting (IPTW) was applied to balance confounders, and Cox proportional hazards models estimated adjusted HRs (aHRs) for receiving two and three or more vaccine doses. Results: The cohort included 105 733 individuals with OUD and 1 185 993 without OUD. Individuals with OUD had a lower hazard of receiving two vaccine doses (aHR: 0.75, 95% CI 0.73 to 0.76) and three or more doses (aHR: 0.69, 95% CI 0.67 to 0.70). The rate of two-dose and three-dose vaccination was also lower among those with OUD (115.3 vs 149.0 per 100 000 person-years and 44.7 vs 77.5 per 100 000 person-years). Conclusion: Individuals with OUD had lower COVID-19 vaccination rates, suggesting barriers to access and uptake. Addressing these disparities through targeted interventions is crucial for equitable public health responses.

  • Open Access

    Defining a low-risk birth cohort: a cohort study comparing two perinatal data sets in Ontario, Canada

    by Elizabeth Darling, Olivia Marquez, Alison Park

    IntroductionThere are two main data sources for perinatal data in Ontario, Canada: the BORN BIS and CIHI-DAD. Such databases are used for perinatal health surveillance and research, and to guide health care related decisions. ObjectivesOur primary objective was to examine the level of agreement between the BIS and CIHI-DAD. Our secondary objectives were to identify the differences between the data sources when identifying a low-risk birth (LRB) cohort and to understand their implications. MethodsWe conducted a population-based cohort study comparing characteristics and clinical outcomes of all linkable births in BIS and CIHI-DAD between 1$^{\rm st}$ April 2012 and 31$^{\rm st}$ March 2018. We excluded out-of-hospital births, those with invalid healthcare numbers, non-Ontario residents and gestational age < 20 weeks. We compared the portion of the cohort that met the criteria of a provincial definition of LRB based on each data source and compared clinical outcomes between the groups. ResultsDuring the study period, 779,979 eligible births were linkable between the two data sources. After applying the LRB exclusions, there were 129,908 cases in the BIS and 136,184 cases in CIHI-DAD. Most exclusion criteria had almost perfect, substantial or moderate agreement. The agreement for non-cephalic presentation and BMI ≥ 40 kg/m2 (kappa coefficients 0.409 and 0.256, respectively) was fair. Comparison between the two LRB cohorts identified differences in the prevalence of cesarean (14.3% BIS versus 12.0% CIHI-DAD) and NICU admission (8.7% BIS versus 7.5% CIHI-DAD) and only 0.01% difference in the prevalence of ICU admission. ConclusionsOverall, we found high levels of agreement between the BIS and CIHI-DAD. Identifying a LRB cohort in either database may be appropriate, with the caveat of appropriate understanding of the collection, coding and definition of certain outcomes. The decision for selecting a database may depend on which variables are most important in a particular analysis.


  • Preconception SGLT2 or DPP4 inhibitor use and adverse pregnancy outcomes

    by Joel G. Ray, Ziv Harel, Richard E. Gilbert, Ron Wald, Howard Berger, Alison L. Park


  • Open Access

    Obstetrical and Perinatal Outcomes in Female Survivors of Childhood and Adolescent Cancer: A Population-Based Cohort Study

    by Alina Zgardau, Joel G Ray, Nancy N Baxter, Chenthila Nagamuthu, Alison L Park, Sumit Gupta, Paul C Nathan

    The likelihood of pregnancy and risk of obstetrical or perinatal complications is inadequately documented in female survivors of pediatric cancer. We assembled a population-based cohort of female survivors of cancer diagnosed at age 21 years and younger in Ontario, Canada, between 1985 and 2012. Survivors were matched 1:5 to women without prior cancer. Multivariable Cox proportional hazards and modified Poisson models assessed the likelihood of a recognized pregnancy and perinatal and maternal complications. A total of 4062 survivors were matched to 20 308 comparisons. Median (interquartile range) age was 11 (4-15) years at cancer diagnosis and 25 (19-31) years at follow-up. By age 30 years, the cumulative incidence of achieving a recognized pregnancy was 22.3% (95% confidence interval [CI] = 20.7% to 23.9%) among survivors vs 26.6% (95% CI = 25.6% to 27.3%) among comparisons (hazard ratio = 0.80, 95% CI = 0.75 to 0.86). A lower likelihood of pregnancy was associated with a brain tumor, alkylator chemotherapy, cranial radiation, and hematopoietic stem cell transplantation. Pregnant survivors were as likely as cancer-free women to carry a pregnancy >20 weeks (relative risk [RR] = 1.01, 95% CI = 0.98 to 1.04). Survivors had a higher relative risk of severe maternal morbidity (RR = 2.31, 95% CI = 1.59 to 3.37), cardiac morbidity (RR = 4.18, 95% CI = 1.89 to 9.24), and preterm birth (RR = 1.57, 95% CI = 1.29 to 1.92). Preterm birth was more likely in survivors treated with hematopoietic stem cell transplantation (allogenic: RR = 8.37, 95% CI = 4.83 to 14.48; autologous: RR = 3.72, 95% CI = 1.66 to 8.35). Survivors of childhood or adolescent cancer are less likely to achieve a pregnancy and, once pregnant, are at higher risk for severe maternal morbidity and preterm birth.


  • Open Access

    Non-ABO red cell antibodies and risk of COVID-19

    by Joel G. Ray, Michael Colacci, Michael J. Schull, Marian J. Vermeulen, Alison L. Park


  • Top Cited Papers
    Open Access

    Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness

    by Joel G. Ray, Md Michael J. Schull, Msc Marian J. Vermeulen, Alison L. Park

    This cohort study examines whether ABO and Rh blood groups are associated with the risk for SARS-CoV-2 infection and severe COVID-19 illness using data from the entire province of Ontario, Canada. Visual Association Between ABO and Rh Blood and SARS-CoV-2 or Severe COVID-19 This cohort study examines whether ABO and Rh blood groups are associated with the risk for SARS-CoV-2 infecti... Background: The ABO and rhesus (Rh) blood groups may influence risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objective: To determine whether ABO and Rh blood grou...


  • Open Access

    Association Between Blunted Glomerular Hyperfiltration in Pregnancy and Severe Maternal Morbidity—A Research Letter

    by Ziv Harel, Alison L. Park, Joel G. Ray

    Background: Glomerular hyperfiltration is one physiological adaptation to pregnancy, marked by a decline in serum creatinine (SCr) concentration by 16 weeks’ gestation. It is not known whether blunted glomerular hyperfiltration leads to adverse maternal outcomes, including severe maternal morbidity (SMM). Objective: To evaluate the association between blunted glomerular hyperfiltration and subsequent SMM or death. Design: Population-based cohort study Setting: Ontario, Canada, from 2008 to 2019. Participants: Included were births among women who had ≥ 1 SCr measured as an outpatient within 10 weeks before conception (“preconception”), and again, at 110/7 to 206/7 weeks’ gestation (“in-pregnancy”). Excluded were women who died before birth, who had end-stage renal disease or kidney transplantation before conception, or whose pre-pregnancy SCr was 125 μmol/L. Exposure: Net glomerular hyperfiltration defined as the preconception minus the in-pregnancy SCr. Measures: The primary study outcome was SMM or death arising from 23 weeks’ gestation up to 42 days after the index birth. Methods: Adjusted relative risks (aRRs) were calculated using Modified Poisson regression per 1-SD net blunting of glomerular hyperfiltration adjusting for important covariates. Results: A total of 10,323 births met all inclusion criteria. The mean (SD) SCr was 61.7 (11.0) μmol/L preconception, 48.0 (9.2) μmol/L in-pregnancy, and the mean net difference 13.6 (8.2) μmol/L. Among these births, the adjusted RR of SMM or death from 23 weeks’ gestation up to 42 days post-partum was 1.16 (95% confidence interval 1.14-1.30) per 1-SD (8.2 μmol/L) net blunting of glomerular hyperfiltration. Limitations: As SCr assessment is not a routine part of pregnancy care, its measurement could have been for a specific health condition thereby imparting selection bias. Conclusions: Blunted glomerular hyperfiltration in pregnancy may identify some women at higher risk of SMM. Further prospective research is needed about the implications of glomerular hyperfiltration in early pregnancy.


  • Population‐based study of serum ferritin in early pregnancy and adverse perinatal outcomes

    by Joel G. Ray, Howard Berger, Alison L. Park

    Background: Chronic placental inflammation is associated with preterm birth (PTB) and perinatal mortality. Ferritin is often elevated in chronic inflammatory conditions, but prior studies of its relation to PTB were restricted to ferritin measurement within pregnancy, were underpowered to detect rarer outcomes, and did not account for pre‐existing maternal inflammatory conditions, such as inflammatory bowel or rheumatological disease.Objectives: To evaluate whether an elevated ferritin level prior to pregnancy is associated with major adverse pregnancy outcomes.Methods: A population‐based cohort study was completed using Ontario, Canada. Included were all Ontarian women with a hospital livebirth or stillbirth at ≥20 weeks’ gestation, 2007‐2018, and serum haemoglobin and ferritin measured as an outpatient within 120 days before conception. Excluded were women with a diagnosed iron overload disorder or a ferritin concentration <15 µg/L. The main exposure was a pre‐pregnancy serum ferritin ≥95th percentile. Study outcomes included PTB < 37 weeks’ gestation, including clinician‐initiated and spontaneous PTB; PTB < 32 weeks; chorioamnionitis; and perinatal death. Relative risks (RR) and 95% confidence intervals (CI) were calculated for each study outcome, comparing a serum ferritin concentration ≥95th vs <5th percentile (the referent), while adjusting maternal age, residence, haemoglobin concentration, diabetes mellitus, inflammatory bowel disease, illicit drug/tobacco use, chronic kidney disease, chronic hypertension, sickle‐cell disease or thalassaemia, and rheumatological conditions.Results: Among 89 847 births, a preconceptional maternal serum ferritin ≥95th (112.0 μg/L) vs <5th (16.9 μg/L) percentile was associated with an adjusted relative risk (aRR) of 1.34 (95% CI 1.15, 1.57) for PTB, including spontaneous and clinician‐initiated PTB. Results were equivocal for chorioamnionitis (aRR 1.23, 95% CI 0.81, 1.86), and there was no association with perinatal mortality (aRR 0.94, 95% CI 0.55, 1.61).Conclusion: A high preconceptional ferritin concentration is associated with some adverse perinatal outcomes.


  • Open Access

    Prenatal Biochemical Screening and a Woman’s Long-Term Risk of Cancer: A Population-Based Cohort Study

    by Alison L Park, Tianhua Huang, Wendy S Meschino, Javaid Iqbal, Joel G Ray

    Background: Some hormones measured in pregnancy are linked to certain hormone-sensitive cancers. We investigated whether routine serum screening in pregnancy is associated with a woman’s subsequent risk of hormone-sensitive cancer. Methods: This population-based cohort study included women aged 12–55 years who underwent prenatal screening between 11 weeks + 0 days of gestation to 20 weeks + 6 days of gestation in Ontario, Canada, 1993–2011, where universal health care is available. The hazard ratio of newly diagnosed breast, ovarian, endometrial, and thyroid cancer—arising at 21 weeks + 0 days of gestation or thereafter—was estimated in association with an abnormally low (≤5th) or high (>95th) percentile multiple of the median (MoM) for alpha-fetoprotein (AFP), total human chorionic gonadotropin (hCG), unconjugated estriol, pregnancy-associated plasma protein A, and dimeric inhibin A. Results: Among 677 247 pregnant women followed for a median of 11.0 years (interquartile range = 7.5–16.1), 7231 (1.07%) developed breast cancer, 515 (0.08%) ovarian cancer, 508 (0.08%) endometrial cancer, and 4105 (0.61%) thyroid cancer. In multivariable adjusted models, abnormally high hCG greater than the 95th percentile MoM was associated with a doubling in the risk of endometrial cancer (adjusted hazard ratio [aHR] = 1.98, 95% confidence interval [CI] = 1.33 to 2.95), and abnormally low AFP at the fifth percentile or less MoM conferred a moderately greater risk of thyroid cancer (aHR = 1.21, 95% CI = 1.07 to 1.38). Abnormally low pregnancy-associated plasma protein A at the fifth percentile or less MoM was not statistically significantly associated with breast cancer after multivariable adjustment (aHR = 1.19, 95% CI = 0.98 to 1.36). Conclusions: Women with abnormally high levels of serum hCG or low AFP in early pregnancy may be at a greater future risk of certain types of hormone-sensitive cancers.


  • Ethnic Differences in Visceral Adiposity Measured in Early Pregnancy

    by Kajenny Srivaratharajah, Beth L. Abramson, Jennifer Jairam, Alison L. Park, Howard Berger, Joel G. Ray